Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412120 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
A Phase 4 study of Ovarian Cancer, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT06412120: Recruiting Phase 4 study of Ovarian Cancer, sponsored by University of Miami.
NCT06412120 is a Phase 4 study of Ovarian Cancer that is actively recruiting participants, run by University of Miami. The registered enrollment target is 70 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06412120, a Phase 4 study of Ovarian Cancer, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investigational medication called niraparib is being tested for the treatment of ovarian cancer. Niraparib works by blocking the ability of cancer cells to fix their genes. Cancer cells with damaged genes have a harder time growing and spreading in the body and can even die.
Primary Outcome
The proportion of participants in this study experiencing any grade or grade 3 or higher of the most common adverse events (AEs), of any treatment attribution, as those previously reported in the PRIMA Trial (NCT02655016). Adverse events will be assessed using the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0. The most common adverse events previously reported include: Anemia, nausea, thrombocytopenia, constipation, fatigue, neutropenia, headache, inso
Conditions Studied
Interventions
- DRUG Niraparib
Study Locations (2)
Florida
- Broward Health - Fort Lauderdale
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2031-06-01 |
| Phase | Phase 4 |
What NCT06412120 shows while recruiting
NCT06412120 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.
NCT06412120 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06412120 about?
NCT06412120 is a clinical study titled "Study Evaluating Safety, Tolerability, and Metabolism of Niraparib". The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investigat...
What is the current status of trial NCT06412120?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2026-06-01. Estimated completion is 2031-06-01.
What conditions does trial NCT06412120 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06412120?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT06412120?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06412120 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06412120's enrollment target sits among peer trials
70 177th of 322 higher than 140 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Serum Folate Levels in Patients Treated With Olaparib
COMPLETED · Phase 4
-
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
COMPLETED · Phase 4
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI